Premium
Clinical correlations of Anti‐Gm1 antibodies in amyotrophic lateral sclerosis and neuropathies
Author(s) -
Lamb Nancy L.,
Patten Bernard M.
Publication year - 1991
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.880141014
Subject(s) - amyotrophic lateral sclerosis , medicine , gammopathy , multifocal motor neuropathy , titer , cervical spondylosis , chronic inflammatory demyelinating polyneuropathy , antibody , clinical significance , neuromuscular disease , immunology , pathology , disease , mismatch negativity , alternative medicine , electroencephalography , psychiatry , monoclonal , monoclonal antibody
Clinical correlations of antiganglioside GM1 antibodies are important because high titers of these antibodies may have therapeutic significance. To further evaluate this significance, we reviewed our experience with 78 patients who had the following diagnoses: amyotrophic lateral sclerosis (ALS), ALS syndromes in patients with gammopathy or thyroid abnormalities, cervical spondylosis simulating ALS, motor neuropathies, and chronic inflammatory demyelinating polyneuropathies (CIDP). Antiganglioside antibody titers were measured “blind” by ELISA assay at the neuromuscular clinical laboratory, Johns Hopkins School of Medicine. We conclude that anti‐GM1 antibodies are found in a wide variety of neuromuscular conditions. Patients with classical ALS had a mean anti‐GM1 antibody titer significantly lower than patients with CIDP or motor neuropathy. Patients with ALS associated with gammopathy or thyroid disorders had higher anti‐GM1 titers than seen in classical ALS. The highest mean titer occurred in patients with CIDP, a treatable neuropathy.